Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

NCT03011034 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Talacotuzumab
DRUG: Daratumumab

Sponsor

Janssen Research & Development, LLC